DJIA 17,813.39 0.00 0.00%
NASDAQ 5,116.14 0.00 0.00%
S&P 500 2,088.87 0.00 0.00%
market minute promo

company name or ticker
Company Photos
(Click to zoom)

Teva (TEVA) Beats on 3Q Earnings & Revenues, Raises Outlook

Cramer -- Why a Pfizer Merger With Allergan Makes Sense

Health Care Sector Update for 10/29/2015: REVA, ALXN

Will Teva (TEVA) Continue with its Earnings Streak in Q3?

Teva Pharmaceutical Industries (TEVA) Stock Storming The Castle Today

With Specialty Pharmaceuticals Down Big, 3 to Buy Now for Huge Potential Gains

3 Stocks Dragging The Drugs Industry Downward

Short Sellers Have Mixed Views on Major Pharma

Will Headwinds Weigh on Novartis' (NVS) Earnings in Q3?

Specialty Drug Classes That Are Costing Consumers an Arm and a Leg

Specialty drug costs as a whole rose by 25% in 2014 according to the nation's largest pharmacy-benefit manager. The following specialty therapy classes appear to be the primary culprits behind these price hikes.
See More Articles...